PA-PMI
19.8.2020 17:02:05 CEST | Business Wire | Press release
Project Management Institute (PMI), the world's leading association for the project management profession, invites professionals across the globe to register for Virtual Experience Series titled, “The Community: Together We Rise ” on 25 August 2020 from 11 a.m. - 5 p.m. Eastern Daylight Time. The second event in this innovative series is headlined by comedian and host of The Daily Show ® program Trevor Noah, and hosted by journalist, talk show host, and executive producer, Tamron Hall. Additionally, more than 20 industry experts will lead thought-provoking sessions, including artificial intelligence thought leader and author of Girl Decoded: A Scientist’s Quest to Reclaim Our Humanity by Bringing Emotional Intelligence to Technology , Dr. Rana el Kaliouby.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200819005404/en/
The Virtual Experience Series connects participants with global innovators, inspirational voices, and project leaders to help them navigate a world defined by challenge, and embrace the opportunity to make a new reality. In the opening session, Trevor Noah will discuss how he taps into his inner project manager to galvanize a community, practice agility daily, and lead a global team. In 2015, Trevor succeeded long-time program host, Jon Stewart, and has received various accolades, including a Primetime Emmy Award win. In response to COVID-19, Trevor began hosting a modified virtual version of The Daily Show called The Daily Social Distancing Show with Trevor Noah to continue tackling the biggest stories in news, politics and pop culture. This year, The Daily Show received eight Emmy nominations.
Participants who want to boost their career or pivot to a new one can discover the Brand You Hub containing useful tips for all professionals looking to adapt and thrive in this new dynamic work environment. They can also network with project professionals in the Networking Hub and join a fireside chat with leaders of Fortune 500 organizations to explore the human side of leading during disruption, as well as lessons and takeaways from the pandemic.
“Now more than ever, PMI’s goal is to bring to the forefront insights and resources that are essential to help empower people to move projects forward and turn ideas into reality,” said Michael DePrisco, vice president, global experience & solutions at PMI. “In our post-COVID new work ecosystem, teams are putting increased emphasis on collaborative leadership and empathy to help deliver value in our virtual workplace. These are what we refer to as ‘power skills’ and PMI is here to provide the resources necessary to build and perfect these skillsets.”
Each month, the Virtual Experience Series will feature a new roster of thought-leading personalities and industry experts. Upcoming series dates and topics include:
- 9 September - A Deep Dive in Organizational Agility: Adaptability, Resilience and Learning
- 20 October - The World: Our Global Impact
- 12 November - A Deep Dive in Business Analysis: Drawing a Map to the Future
- 9 December - The Future: Forging Our Path Forward
Registration for PMI members is $99 for a single experience or $359 for the entire series. Registration for non-members is $149 for a single experience or $899 for the event series. Purchasing a series pass includes complimentary on-demand access to the PMI® Talent and Technology Symposium, which took place in June, and select recorded sessions for attendees to peruse through January 2021. Each session is eligible for professional development units (PDUs) toward maintaining PMI® certifications.
For more information on this event and to register, visit experience.pmi.org .
About Project Management Institute (PMI)
Project Management Institute (PMI) is the world's leading association for those who consider project, program or portfolio management their profession. Through global advocacy, collaboration, education and research, we work to prepare more than three million professionals around the world for The Project Economy: the coming economy in which work, and individuals, are organized around projects, products, programs and value streams. Now 50 years in the making, we work in nearly every country around the world to advance careers, improve organizational success and further mature the project management profession through globally-recognized standards, certifications, communities, resources, tools, academic research, publications, professional development courses and networking opportunities. As part of the PMI family, ProjectManagement.com® website creates online global communities that deliver more resources, better tools, larger networks and broader perspectives. Visit us at www.PMI.org , www.projectmanagement.com , www.facebook.com/PMInstitute and on Twitter @PMInstitute .
“The Daily Show” is a registered mark of Comedy Partners.
“PMI” and “Projectmanagement.com” are registered marks of Project Management Institute, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200819005404/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom